VERONA PHARMA P/S (NASDAQ:VRNA) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 900 shares, a growth of 80.0% from the July 31st total of 500 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s stock are sold short.
Several brokerages have recently issued reports on VRNA. Wedbush reiterated an “outperform” rating and issued a $58.00 price objective on shares of VERONA PHARMA P/S in a research note on Monday, July 29th. Zacks Investment Research raised VERONA PHARMA P/S from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Tuesday, July 16th. Finally, ValuEngine upgraded VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Shares of VRNA stock traded down $0.24 during trading hours on Wednesday, reaching $4.36. 2,355 shares of the stock were exchanged, compared to its average volume of 6,834. The business’s fifty day moving average is $4.35 and its two-hundred day moving average is $5.51. The firm has a market capitalization of $57.40 million, a P/E ratio of -2.16 and a beta of -1.01. VERONA PHARMA P/S has a 12-month low of $3.65 and a 12-month high of $14.50.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.